The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole

Shenoy, R K and Suma, T K and John, A and Arun, S R and Kumaraswami, V and Fleckenstein, L L and Na-Bangchang, K (2002) The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole. Annals of Tropical Medicine and Parasitology, 96 (6). pp. 603-614. ISSN 0003-4983‎

PDF 200235.pdf - Published Version Restricted to Registered users only Download (227kB) | Request a copy

Abstract

The pharmacokinetics, safety and tolerability of single, oral doses of diethylcarbamazine (DEC) and albendazole, given alone or in combination, were investigated in a double-blind, randomized and placebo-controlled trial involving 42 amicro� laraemic subjects living in an area of India where lymphatic � lariasis is endemic. The subjects (34 males and eight females, aged 18–52 years and weighing 46–66.5 kg ) were randomly allocated to one of the three drug groups. Fourteen were given just DEC (6 mg/kg ), another 14 were given just albendazole (400 mg) and the remaining 14 were given both DEC (6 mg/kg) and albendazole (400 mg). Blood samples for pharmacokinetic study were collected at speci� ed intervals before and after drug administration. Plasma concentrations of DEC and albendazole/albendazole sulphoxide were estimated using gas chromatography and HPLC, respectively. The safety and tolerability of the treatments were evaluated through clinical and laboratory assessments. Both the DEC and albendazole were well tolerated when given alone or in combination, no adverse events being observed. In all three treatment groups, the drugs were rapidly absorbed from the gastro–intestinal tract although there was marked inter-individual variation. The pharmacokinetics of DEC, albendazole and albendazole sulphoxide were similar, whether each drug was given alone or in combination. These results indicate that there is no adverse pharmacokinetic or pharmacodynamic reason why DEC and albendazole should not be co-administered to control lymphatic � filariasis.

Item Type:	Article
Subjects:	Tuberculosis > Laboratory Research > Biochemical
Divisions:	Basic Science Research > Biochemistry
Depositing User:	Dr. Rathinasabapati R
Date Deposited:	11 Nov 2013 11:06
Last Modified:	10 Mar 2016 04:47
URI:	http://eprints.nirt.res.in/id/eprint/583

Actions (login required)

View Item